Zaręba Paula, Dudek Magdalena, Lustyk Klaudia, Siwek Agata, Starowicz Gabriela, Bednarski Marek, Nowiński Leszek, Raźny Katarzyna, Sapa Jacek, Malawska Barbara, Kulig Katarzyna
Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.
Department of Pharmacodynamics, Jagiellonian University, Collegium Medicum, 9, Medyczna Street, PL 30-688 Kraków, Poland.
Bioorg Med Chem. 2015 May 1;23(9):2104-11. doi: 10.1016/j.bmc.2015.03.009. Epub 2015 Mar 9.
This study focused on a series of pyrrolidin-2-one derivatives connected via two or four methylene units to arylpiperazine fragment. The compounds obtained for α₁- and α₂-adrenoceptors were assessed. The compound with highest affinity for the α₁-adrenoceptors was 1-{4-[4-(2-chloro-phenyl)-piperazin-1-yl]-butyl}-pyrrolidin-2-one (10 h) with pKi=7.30. Compound with pKi (α₁) ⩾6.44 were evaluated in functional bioassays for intrinsic activity at α₁A- and α₁B-adrenoceptors. All compounds tested were antagonists of the α₁B-adrenoceptors. Additionally, compounds 10e and 10h were α₁A-adrenoceptors antagonist. The dual α₁A-/α₁B-adrenoceptors antagonists, compounds 10e and 10h were also tested in vivo for their hypotensive activity in rats. These compounds, when dosed of 1.0 mg/kg iv in normotensive, anesthetized rats, significantly decreased systolic and diastolic pressure and their hypotensive effects lasted for longer than one hour.
本研究聚焦于一系列通过两个或四个亚甲基单元与芳基哌嗪片段相连的吡咯烷-2-酮衍生物。对所获得的针对α₁和α₂肾上腺素能受体的化合物进行了评估。对α₁肾上腺素能受体具有最高亲和力的化合物是1-{4-[4-(2-氯苯基)-哌嗪-1-基]-丁基}-吡咯烷-2-酮(10h),其pKi = 7.30。对pKi(α₁)⩾6.44的化合物在功能性生物测定中评估其对α₁A和α₁B肾上腺素能受体的内在活性。所有测试的化合物都是α₁B肾上腺素能受体的拮抗剂。此外,化合物10e和10h是α₁A肾上腺素能受体拮抗剂。双α₁A/α₁B肾上腺素能受体拮抗剂化合物10e和10h也在大鼠体内测试了它们的降压活性。这些化合物在正常血压、麻醉大鼠中静脉注射1.0mg/kg时,显著降低收缩压和舒张压,其降压作用持续超过一小时。